

# Life Sciences Consortium of the CEO Roundtable on Cancer

**David Reese, MD**

Executive Vice President, R&D, Amgen; Co-Chair, Life Sciences Consortium

# Life Sciences Consortium

- Formed in 2005 of *CEO Roundtable on Cancer* Members partnering with pharma, biotech, CROs, and industry
- Mission and Directive
  - “...Bold & Venturesome”
  - Conduct transformative cancer research to deliver novel and effective therapies ... faster
  - Enhance and accelerate clinical trial delivery and streamline regulatory process
  - Create pre-competitive pool of intellectual property that enhances drug discovery and development


# Project Data Sphere<sup>®</sup> : Role

- Changing status quo by bringing together innovators and disrupters

- Facilitate collaborations with siloed entities
- Foster out of the box ideas by asking challenging questions to key stakeholders
- Create innovative ecosystem to advance cancer research

- Accelerating cancer research

- Data enabler and aggregator
- Data-sharing platform for global cancer research community
- Safe harbor and neutral convener



# Project Data Sphere<sup>®</sup> : Future prospects

## ● Opportunities


- *Expand* data types
- *Enrich* data repository
- *Explore* new partnerships

## ● Outcomes

- Novel research questions and methodologies
- Open access data sharing platform

## ● Outreach

- Conferences, Journals, Op-ed



# Open Access Data Sharing

## Sharing of cancer trial data is moving to center stage

*New England Journal of Medicine*  
(23-March-2017)



The NEW ENGLAND  
JOURNAL of MEDICINE

### SOUNDING BOARD

#### Advantages of a Truly Open-Access Data-Sharing Model

Monica M. Bertagnolli, M.D., Oliver Sartor, M.D., Bruce A. Chabner, M.D., Mace L. Rothenberg, M.D., Sean Khozin, M.D., M.P.H., Charles Hugh-Jones, M.D., David M. Reese, M.D., and Martin J. Murphy, D.Med.Sc., Ph.D.

sponsible and meaningful way. The cancer research community, encouraged by recommendations from the Beau Biden Cancer Moonshot, is finally moving data sharing forward from its traditional, largely unfunded, place at the end of the long list of clinical research responsibilities to center stage.

Thus, the PDS Prostate Cancer DREAM Challenge confirmed that an open-access model empowers global communities of scientists from diverse backgrounds and promotes crowd-sourced solutions to important clinical problems. This level of engagement is not possible with gate-keeper models.

*N. Engl. J. Med.* 376:12, March 23, 2017